Sharemarkets have reacted strongly to news of a possible Covid-19 vaccine breakthrough, with investors shifting out of defensive stocks and into companies with more exposure to an economic rebound.
Yesterday pharmaceutical giant Pfizer and research partner Biontech announced early results of a
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
